Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment

Biological Psychiatry

Volumn 80, Issue 6, 2016, Pages 457-468

  Ren, Zhen ^a   Pribiag, Horia ^b   Jefferson, Sarah J ^a   Shorey, Matthew ^a   Fuchs, Thomas ^a   Stellwagen, David ^b   Luscher, Bernhard ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Antidepressant drug mechanisms; GABA; Glutamate; Homeostatic synaptic plasticity; Major depressive disorder; Neuroligin

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR GAMMA2; AMPA RECEPTOR; ANTIDEPRESSANT AGENT; GEPHYRIN; GLUTAMATE RECEPTOR 2; GLUTAMATE RECEPTOR 3; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; NEUROLIGIN 1; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; GABRG2 PROTEIN, MOUSE; GLUTAMIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR CINGULATE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BIOTINYLATION; BRAIN CELL CULTURE; CELL DENSITY; CELL SURFACE; CONTROLLED STUDY; DORSAL HIPPOCAMPUS; DOWN REGULATION; DRUG EFFICACY; EMBRYO; FACE VALIDITY; FUNCTIONAL DISEASE; GABAERGIC TRANSMISSION; GLUTAMATERGIC SYNAPSE; HETEROZYGOSITY; HIPPOCAMPAL CA1 REGION; HOMEOSTASIS; MAJOR DEPRESSION; MEDIAL PREFRONTAL CORTEX; MOUSE; NONHUMAN; PREDICTIVE VALIDITY; PRELIMBIC CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; SINGLE DRUG DOSE; SYNAPTIC INHIBITION; SYNAPTIC TRANSMISSION; UPREGULATION; ANIMAL; ANIMAL BEHAVIOR; BIOSYNTHESIS; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; GENETICS; HIPPOCAMPUS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PREFRONTAL CORTEX; SYNAPSE;

ANIMALS; BEHAVIOR, ANIMAL; DEPRESSIVE DISORDER, MAJOR; DOWN-REGULATION; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HIPPOCAMPUS; HOMEOSTASIS; KETAMINE; MICE; PREFRONTAL CORTEX; RECEPTORS, AMPA; RECEPTORS, GABA-A; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPSES;

EID: 84962421648     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2016.02.009     Document Type: Article

References (71)

1. 1 Kessler, R.C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K.R., et al. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA 289 (2003), 3095–3105.
2. 2 McIntyre, R.S., Filteau, M.J., Martin, L., Patry, S., Carvalho, A., Cha, D.S., et al. Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach. J Affect Disord 156 (2014), 1–7.
3. 3 Willner, P., Scheel-Kruger, J., Belzung, C., The neurobiology of depression and antidepressant action. Neurosci Biobehav Rev 37 (2013), 2331–2371.
4. 4 Sanacora, G., Mason, G.F., Rothman, D.L., Behar, K.L., Hyder, F., Petroff, O.A., et al. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 56 (1999), 1043–1047.
5. 5 Hasler, G., van der Veen, J.W., Tumonis, T., Meyers, N., Shen, J., Drevets, W.C., Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 64 (2007), 193–200.
6. 6 Gabbay, V., Mao, X., Klein, R.G., Ely, B.A., Babb, J.S., Panzer, A.M., et al. Anterior cingulate cortex gamma-aminobutyric acid in depressed adolescents: Relationship to anhedonia. Arch Gen Psychiatry 69 (2012), 139–149.
7. 7 Bhagwagar, Z., Wylezinska, M., Jezzard, P., Evans, J., Ashworth, F., Sule, A., et al. Reduction in occipital cortex gamma-aminobutyric acid concentrations in medication-free recovered unipolar depressed and bipolar subjects. Biol Psychiatry 61 (2007), 806–812.
8. 8 Price, R.B., Shungu, D.C., Mao, X., Nestadt, P., Kelly, C., Collins, K.A., et al. Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: Relationship to treatment resistance in major depressive disorder. Biol Psychiatry 65 (2009), 792–800.
9. 9 Croarkin, P.E., Levinson, A.J., Daskalakis, Z.J., Evidence for GABAergic inhibitory deficits in major depressive disorder. Neurosci Biobehav Rev 35 (2011), 818–825.
10. 10 Feyissa, A.M., Woolverton, W.L., Miguel-Hidalgo, J.J., Wang, Z., Kyle, P.B., Hasler, G., et al. Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 34 (2010), 279–283.
11. 11 Guilloux, J.P., Douillard-Guilloux, G., Kota, R., Wang, X., Gardier, A.M., Martinowich, K., et al. Molecular evidence for BDNF- and GABA-related dysfunctions in the amygdala of female subjects with major depression. Mol Psychiatry 17 (2012), 1130–1142.
12. 12 Klumpers, U.M., Veltman, D.J., Drent, M.L., Boellaard, R., Comans, E.F., Meynen, G., et al. Reduced parahippocampal and lateral temporal GABAA-[11C]flumazenil binding in major depression: Preliminary results. Eur J Nucl Med Mol Imaging 37 (2010), 565–574.
13. 13 Sibille, E., Morris, H.M., Kota, R.S., Lewis, D.A., GABA-related transcripts in the dorsolateral prefrontal cortex in mood disorders. Int J Neuropsychopharmacol 14 (2011), 721–734.
14. 14 Rajkowska, G., O'Dwyer, G., Teleki, Z., Stockmeier, C.A., Miguel-Hidalgo, J.J., GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropsychopharmacology 32 (2007), 471–482.
15. 15 Luscher, B., Shen, Q., Sahir, N., The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry 16 (2011), 383–406.
16. 16 Levinson, A.J., Fitzgerald, P.B., Favalli, G., Blumberger, D.M., Daigle, M., Daskalakis, Z.J., Evidence of cortical inhibitory deficits in major depressive disorder. Biol Psychiatry 67 (2010), 458–464.
17. 17 Sanacora, G., Gueorguieva, R., Epperson, C.N., Wu, Y.T., Appel, M., Rothman, D.L., et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 61 (2004), 705–713.
18. 18 Hashimoto, K., Sawa, A., Iyo, M., Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 62 (2007), 1310–1316.
19. 19 Niciu, M.J., Ionescu, D.F., Richards, E.M., Zarate, C.A. Jr, Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm 121 (2014), 907–924.
20. 20 Paul, I.A., Skolnick, P., Glutamate and depression: Clinical and preclinical studies. Ann N Y Acad Sci 1003 (2003), 250–272.
21. 21 Feyissa, A.M., Chandran, A., Stockmeier, C.A., Karolewicz, B., Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 33 (2009), 70–75.
22. 22 Pittenger, C., Sanacora, G., Krystal, J.H., The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets 6 (2007), 101–115.
23. 23 Zarate, C.A. Jr, Singh, J.B., Carlson, P.J., Brutsche, N.E., Ameli, R., Luckenbaugh, D.A., et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63 (2006), 856–864.
24. 24 Abdallah, C.G., Averill, L.A., Krystal, J.H., Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. Ann N Y Acad Sci 1344 (2015), 66–77.
25. 25 Moghaddam, B., Adams, B., Verma, A., Daly, D., Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17 (1997), 2921–2927.
26. 26 Li, N., Lee, B., Liu, R.J., Banasr, M., Dwyer, J.M., Iwata, M., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329 (2010), 959–964.
27. 27 Ionescu, D.F., Luckenbaugh, D.A., Niciu, M.J., Richards, E.M., Slonena, E.E., Vande Voort, J.L., et al. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry 75 (2014), e932–938.
28. 28 Turrigiano, G., Homeostatic synaptic plasticity: Local and global mechanisms for stabilizing neuronal function. Cold Spring Harb Perspect Biol, 4, 2012, a005736.
29. 29 Watt, A.J., van Rossum, M.C., MacLeod, K.M., Nelson, S.B., Turrigiano, G.G., Activity coregulates quantal AMPA and NMDA currents at neocortical synapses. Neuron 26 (2000), 659–670.
30. 30 Peng, Y.R., Zeng, S.Y., Song, H.L., Li, M.Y., Yamada, M.K., Yu, X., Postsynaptic spiking homeostatically induces cell-autonomous regulation of inhibitory inputs via retrograde signaling. J Neurosci 30 (2010), 16220–16231.
31. 31 Rannals, M.D., Kapur, J., Homeostatic strengthening of inhibitory synapses is mediated by the accumulation of GABA(A) receptors. J Neurosci 31 (2011), 17701–17712.
32. 32 Pribiag, H., Peng, H., Shah, W.A., Stellwagen, D., Carbonetto, S., Dystroglycan mediates homeostatic synaptic plasticity at GABAergic synapses. Proc Natl Acad Sci U S A 111 (2014), 6810–6815.
33. 33 Smith, K.S., Rudolph, U., Anxiety and depression: Mouse genetics and pharmacological approaches to the role of GABA(A) receptor subtypes. Neuropharmacology 62 (2012), 54–62.
34. 34 Crestani, F., Lorez, M., Baer, K., Essrich, C., Benke, D., Laurent, J.P., et al. Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for threat cues. Nat Neurosci 2 (1999), 833–839.
35. 35 Essrich, C., Lorez, M., Benson, J., Fritschy, J.-M., Luscher, B., Postsynaptic clustering of major GABA(A) receptor subtypes requires the gamma2 subunit and gephyrin. Nat Neurosci 1 (1998), 563–571.
36. 36 Lorez, M., Benke, D., Luscher, B., Mohler, H., Benson, J.A., Single-channel properties of neuronal GABAA receptors from mice lacking the 2 subunit. J Physiol 527:pt 1 (2000), 11–31.
37. 37 Earnheart, J.C., Schweizer, C., Crestani, F., Iwasato, T., Itohara, S., Mohler, H., et al. GABAergic control of adult hippocampal neurogenesis in relation to behavior indicative of trait anxiety and depression states. J Neurosci 27 (2007), 3845–3854.
38. 38 Shen, Q., Lal, R., Luellen, B.A., Earnheart, J.C., Andrews, A.M., Luscher, B., Gamma-aminobutyric acid-type A receptor deficits cause hypothalamic-pituitary-adrenal axis hyperactivity and antidepressant drug sensitivity reminiscent of melancholic forms of depression. Biol Psychiatry 68 (2010), 512–520.
39. 39 Leal, S.L., Tighe, S.K., Jones, C.K., Yassa, M.A., Pattern separation of emotional information in hippocampal dentate and CA3. Hippocampus 24 (2014), 1146–1155.
40. 40 Fujii, T., Saito, D.N., Yanaka, H.T., Kosaka, H., Okazawa, H., Depressive mood modulates the anterior lateral CA1 and DG/CA3 during a pattern separation task in cognitively intact individuals: A functional MRI study. Hippocampus 24 (2014), 214–224.
41. 41 Vithlani, M., Hines, R.M., Zhong, P., Terunuma, M., Hines, D.J., Revilla-Sanchez, R., et al. The ability of BDNF to modify neurogenesis and depressive-like behaviors is dependent upon phosphorylation of tyrosine residues 365/367 in the GABA(A)-receptor gamma2 subunit. J Neurosci 33 (2013), 15567–15577.
42. 42 Gunther, U., Benson, J., Benke, D., Fritschy, J.M., Reyes, G., Knoflach, F., et al. Benzodiazepine-insensitive mice generated by targeted disruption of the gamma 2 subunit gene of gamma-aminobutyric acid type A receptors. Proc Natl Acad Sci U S A 92 (1995), 7749–7753.
43. 43 Schweizer, C., Balsiger, S., Bluethmann, H., Mansuy, M., Fritschy, J.M., Mohler, H., et al. The gamma2 subunit of GABA(A) receptors is required for maintenance of receptors at mature synapses. Mol Cell Neurosci 24 (2003), 442–450.
44. 44 Autry, A.E., Adachi, M., Nosyreva, E., Na, E.S., Los, M.F., Cheng, P.F., et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475 (2011), 91–95.
45. 45 Yuan, X., Yao, J., Norris, D., Tran, D.D., Bram, R.J., Chen, G., et al. Calcium-modulating cyclophilin ligand regulates membrane trafficking of postsynaptic GABA(A) receptors. Mol Cell Neurosci 38 (2008), 277–289.
46. 46 Terunuma, M., Xu, J., Vithlani, M., Sieghart, W., Kittler, J., Pangalos, M., et al. Deficits in phosphorylation of GABA(A) receptors by intimately associated protein kinase C activity underlie compromised synaptic inhibition during status epilepticus. J Neurosci 28 (2008), 376–384.
47. 47 Alldred, M.J., Mulder-Rosi, J., Lingenfelter, S.E., Chen, G., Luscher, B., Distinct gamma2 subunit domains mediate clustering and synaptic function of postsynaptic GABAA receptors and gephyrin. J Neurosci 25 (2005), 594–603.
48. 48 Liu, Y., Wong, T.P., Aarts, M., Rooyakkers, A., Liu, L., Lai, T.W., et al. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci 27 (2007), 2846–2857.
49. 49 Miller, O.H., Yang, L., Wang, C.C., Hargroder, E.A., Zhang, Y., Delpire, E., et al. GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. eLife 3, 2014, e03581.
50. 50 Budreck, E.C., Kwon, O.B., Jung, J.H., Baudouin, S., Thommen, A., Kim, H.S., et al. Neuroligin-1 controls synaptic abundance of NMDA-type glutamate receptors through extracellular coupling. Proc Natl Acad Sci U S A 110 (2013), 725–730.
51. 51 Ren, Z., Sahir, N., Murakami, S., Luellen, B.A., Earnheart, J.C., Lal, R., et al. Defects in dendrite and spine maturation and synaptogenesis associated with an anxious-depressive-like phenotype of GABAA receptor-deficient mice. Neuropharmacology 88 (2015), 171–179.
52. 52 Sato, Y., Seo, N., Kobayashi, E., Genetic background differences between FVB and C57BL/6 mice affect hypnotic susceptibility to pentobarbital, ketamine and nitrous oxide, but not isoflurane. Acta Anaesthesiol Scand 50 (2006), 553–556.
53. 53 Bechtholt-Gompf, A.J., Smith, K.L., John, C.S., Kang, H.H., Carlezon, W.A. Jr, Cohen, B.M., et al. CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy. Psychopharmacology 215 (2011), 689–695.
54. 54 Samuels, B.A., Hen, R., Neurogenesis and affective disorders. Eur J Neurosci 33 (2011), 1152–1159.
55. 55 Chang, C.H., Chen, M.C., Lu, J., Effect of antidepressant drugs on the vmPFC-limbic circuitry. Neuropharmacology 92 (2015), 116–124.
56. 56 Kallarackal, A.J., Kvarta, M.D., Cammarata, E., Jaberi, L., Cai, X., Bailey, A.M., et al. Chronic stress induces a selective decrease in AMPA receptor-mediated synaptic excitation at hippocampal temporoammonic-CA1 synapses. J Neurosci 33 (2013), 15669–15674.
57. 57 Schneider, P.G., Rodriguez de Lores Arnaiz, G., Ketamine prevents seizures and reverses changes in muscarinic receptor induced by bicuculline in rats. Neurochem Int 62 (2013), 258–264.
58. 58 Chen, J.W., Wasterlain, C.G., Status epilepticus: Pathophysiology and management in adults. Lancet Neurol 5 (2006), 246–256.
59. 59 Synowiec, A.S., Singh, D.S., Yenugadhati, V., Valeriano, J.P., Schramke, C.J., Kelly, K.M., Ketamine use in the treatment of refractory status epilepticus. Epilepsy Res 105 (2013), 183–188.
60. 60 Thompson, S.M., Kallarackal, A.J., Kvarta, M.D., Van Dyke, A.M., LeGates, T.A., Cai, X., An excitatory synapse hypothesis of depression. Trends Neurosci 38 (2015), 279–294.
61. 61 Garcia, L.S., Comim, C.M., Valvassori, S.S., Reus, G.Z., Stertz, L., Kapczinski, F., et al. Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats. Prog Neuropsychopharmacol Biol Psychiatry 33 (2009), 450–455.
62. 62 Hewitt, S.A., Bains, J.S., Brain-derived neurotrophic factor silences GABA synapses onto hypothalamic neuroendocrine cells through a postsynaptic dynamin-mediated mechanism. J Neurophysiol 95 (2006), 2193–2198.
63. 63 Wake, H., Watanabe, M., Moorhouse, A.J., Kanematsu, T., Horibe, S., Matsukawa, N., et al. Early changes in KCC2 phosphorylation in response to neuronal stress result in functional downregulation. J Neurosci 27 (2007), 1642–1650.
64. 64 MacKenzie, G., Maguire, J., Chronic stress shifts the GABA reversal potential in the hippocampus and increases seizure susceptibility. Epilepsy Res 109 (2015), 13–27.
65. 65 Chubykin, A.A., Atasoy, D., Etherton, M.R., Brose, N., Kavalali, E.T., Gibson, J.R., et al. Activity-dependent validation of excitatory versus inhibitory synapses by neuroligin-1 versus neuroligin-2. Neuron 54 (2007), 919–931.
66. 66 Gourley, S.L., Kedves, A.T., Olausson, P., Taylor, J.R., A history of corticosterone exposure regulates fear extinction and cortical NR2B, GluR2/3, and BDNF. Neuropsychopharmacology 34 (2009), 707–716.
67. 67 Yuen, E.Y., Wei, J., Liu, W., Zhong, P., Li, X., Yan, Z., Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex. Neuron 73 (2012), 962–977.
68. 68 Li, N., Liu, R.J., Dwyer, J.M., Banasr, M., Lee, B., Son, H., et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69 (2011), 754–761.
69. 69 Cai, X., Kallarackal, A.J., Kvarta, M.D., Goluskin, S., Gaylor, K., Bailey, A.M., et al. Local potentiation of excitatory synapses by serotonin and its alteration in rodent models of depression. Nat Neurosci 16 (2013), 464–472.
70. 70 Klausberger, T., GABAergic interneurons targeting dendrites of pyramidal cells in the CA1 area of the hippocampus. Eur J Neurosci 30 (2009), 947–957.
71. 71 Lin, L.C., Sibille, E., Somatostatin, neuronal vulnerability and behavioral emotionality. Mol Psychiatry 20 (2015), 377–387.